TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1609035
Drug: Dose reductions
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose reductions (10% twice weekly for 5 weeks to zero dose, then placebo for 2 weeks)
Study: 1609035
Drug: Stable dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stable dose for 7 weeks
Study: 1609035
Drug: Discontinuation trial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation trial (n = 51)
Study: 3086061
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg enteric-coated granules, once daily for nine days
Study: 30220235
Drug: Nintedanib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nintedanib plus Sildenafil (nintedanib at a dose of 150 mg twice daily plus sildenafil at a dose of 20 mg three times daily)
Study: 30220235
Drug: Nintedanib (nintedanib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nintedanib (nintedanib at a dose of 150 mg twice daily plus placebo three times daily)
Study: 19126851
Drug: Concurrent tracking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent tracking task during stepping trials
Study: 19126851
Drug: No concurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: No concurrent tracking task during stepping trials
Study: 12967799
Drug: Ahmed glaucoma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ahmed glaucoma valve implant
Study: 10898322
Drug: Famciclovir 500
Normalized name: famciclovir 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famciclovir 500 mg three times daily (tid)
Study: 10898322
Drug: Famciclovir 125
Normalized name: famciclovir 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famciclovir 125 mg, 250 mg, 500 mg three times daily (tid)
Study: 9273203
Drug: 1% histamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% histamine solution
Study: 31433304
Drug: DOR 100
Normalized name: minoxidil
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DOR 100 mg + TDF 300 mg (Study 1)
Study: 31433304
Drug: DOR 100
Normalized name: minoxidil
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DOR 100 mg + 3TC 300 mg + TDF 300 mg (Study 2)
Study: 31433304
Drug: 3TC 300
Normalized name: 3TC 300 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3TC 300 mg + TDF 300 mg (Study 2)
Study: 24594678
Drug: 200 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 μg of LSD
Study: 24594678
Drug: 20 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 μg of LSD (with crossover to 200 μg after unmasking)
Study: 19562652
Drug: Cranberry (C)
DrugBank: Cranberry (DB10631)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry (C) two times daily (C, C; n = 10 pregnant)
Study: 19562652
Drug: Placebo two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo two times daily (P, P; n = 8 pregnant)
Study: 19102746
Drug: Artemether-lumefantrine tablets
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemether-lumefantrine tablets (Coartem)
Study: 19102746
Drug: Artemether-lumefantrine suspension
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemether-lumefantrine suspension (Co-artesiane)
Study: 15480571
Drug: Strontium ranelate
Normalized name: Strontium ranelate
DrugBank: Strontium ranelate (DB09267)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Strontium ranelate (2 g daily)
Study: 7598056
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g alcohol/d for three menstrual cycles
Study: 2115613
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose (HD) of 0.1 mg/sqm, three times a week
Study: 2115613
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose (LD) of 0.01 mg/sqm, three times a week
Study: 2115613
Drug: Human recombinant
Normalized name: Human recombinant AP
DrugBank: Recombinant human alkaline phosphatase (DB17672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human recombinant gamma‐interferon (r‐IFN‐gamma) therapy
Study: 31060615
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg elemental iron and 2.8 mg folic acid
Study: 28586713
Drug: Guided Internet-Based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided Internet-Based Cognitive Behavior Therapy (ICBT) for 8 weeks
Study: 26125951
Drug: Tier 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tier 2 narrative language intervention, small-group (4:1), 15-20 min, twice a week, for 9 weeks
Study: 1312770
Drug: Intra-arterial therapy
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial therapy
Study: 24174612
Drug: Motivational enhancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational enhancement treatment plus brief physician advice and 8 weeks of nicotine replacement therapy (NRT)
Study: 20593912
Drug: Budesonide/formoterol fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol fixed maintenance dose (640 microg/18 microg per day)
Study: 20593912
Drug: Budesonide/formoterol maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol maintenance and reliever therapy (320 microg/9 microg per day plus additional inhalations as needed)
Study: 20593912
Drug: Salmeterol/fluticasone propionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol/fluticasone propionate fixed maintenance dose (100 microg/500 microg per day plus terbutaline as needed)
Study: 10098429
Drug: Adjuvant postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant postoperative radiotherapy (conventional roentgen, electron beams, and high‐energy photon beams) with a target dose of 38‐48 Gy, administered in daily fractions of 1.9‐2.4 Gy, 5 days/week.
Study: 1974513
Drug: Acute administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acute administration of 50 mg carvedilol
Study: 31254190
Drug: Monthly ring
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly ring
Study: 28759403
Drug: Metformin 1
Normalized name: metformin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1 g/d for 6 months
Study: 23771713
Drug: Conservative drug
Normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative drug therapy
Study: 12652148
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin infusion with bedside aPTT testing and computerized algorithmic adjustment
Study: 7742156
Drug: New microemulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: New microemulsion oral formulation (NEO)
Study: 7742156
Drug: Soft gelatine
Normalized name: Gelatin
DrugBank: Gelatin (DB11242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft gelatine capsule (SGC)
Study: 28319494
Drug: Heparin derivatives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin derivatives
Study: 26552068
Drug: 1.2% atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2% atorvastatin
Study: 24640583
Drug: RLX (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: RLX (40 mcg/d) plus rehabilitation
Study: 21878434
Drug: Darexaban 10
Normalized name: Darexaban
DrugBank: Darexaban (DB12289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darexaban 10 mg o.d.
Study: 21878434
Drug: Darexaban 30
Normalized name: Darexaban
DrugBank: Darexaban (DB12289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darexaban 30 mg b.i.d.
Study: 21878434
Drug: Darexaban 60
Normalized name: Darexaban
DrugBank: Darexaban (DB12289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darexaban 60 mg o.d.
Study: 17492272
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg intravenous citalopram
Study: 15364775
Drug: Monoclonal antibody
Normalized name: Monoclonal antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibody recognizing IL-8 (800-mg loading dose; 400-mg subsequent doses)
Study: 15364775
Drug: Placebo (active
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (active buffer solution)
Study: 11277373
Drug: Routine daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine daily chest radiographs
Study: 9766831
Drug: Oral appliances
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral appliances for the management of chronic myalgia of the jaw muscles
Study: 2596599
Drug: Prednisone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (20 mg three times daily for 5 days)
Study: 4119162
Drug: Ragweed extract
Normalized name: Ragweed pollen extract
DrugBank: Ragweed pollen extract (DB05368)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ragweed extract immunotherapy
Study: 23290075
Drug: Herbal medicine
Normalized name: Herbal medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal medicine (Shaofu Zhuyu formula concentrated-granule, SFZYFG) therapy
Study: 18442638
Drug: Metformin (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (0.5 g 3 times a day)
Study: 15890685
Drug: AMD3100 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMD3100 plus G-CSF (A + G)
Study: 15890685
Drug: G-CSF alone
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF alone (G)
Study: 11641591
Drug: Fluindione plus
Normalized name: fluindione
DrugBank: Fluindione (DB13136)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluindione plus aspirin (100 mg)
Study: 11641591
Drug: Fluindione plus
Normalized name: fluindione
DrugBank: Fluindione (DB13136)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluindione plus placebo (anticoagulant alone)
Study: 9617462
Drug: r‐hEPO (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: r‐hEPO (all doses)
Study: 27625301
Drug: MK‐7 375 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK‐7 375 µg for 12 months
Study: 19962839
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care provided at month 2
Study: 15751670
Drug: Pentoxifylline (PTX)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PTX) 200 mg added to 500 mL NaCl and perfused for 180 min after induction of anaesthesia and 100 mg PTX added to warm cardioplegic solution
Study: 15751670
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (saline solution as placebo)
Study: 2493732
Drug: Continuous nitroglycerin
Normalized name: nitroglycerin Extended Release Oral Tablet [Nitrocontin Continus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous nitroglycerin therapy (active drug patches worn for 24 hours)
Study: 2493732
Drug: Intermittent nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent nitroglycerin therapy (12-hour active drug followed by 12-hour nitrate-free period)
Study: 25741640
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine administered with SoloSTAR® or ClikSTAR® pens
Study: 17185119
Drug: Acetaminophen and
Normalized name: Acetaminophen and Aspirin Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen and Ibuprofen
Study: 15379308
Drug: Periocline (2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periocline (2% minocycline hydrochloride ointment)
Study: 9771304
Drug: Tropisetron 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron 0.1 mg kg‐1
Study: 18332472
Drug: Exemestane (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exemestane (25 mg/d orally)
Study: 16567978
Drug: MMR and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMR and varicella vaccine followed by Hib/HepB and DTaP 42 days later
Study: 14562776
Drug: Totally intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Totally intravenous anaesthesia (propofol and remifentanil)
Study: 10801250
Drug: Lactate capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactate capsule (control)
Study: 3912190
Drug: Baclofen 10
Normalized name: baclofen 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen 10 mg orally
Study: 31314965
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (combination prevention intervention with universal antiretroviral therapy [ART])
Study: 24724863
Drug: Prophylactic platelet
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic platelet transfusions at counts of fewer than 10 × 10(9) /L
Study: 22607479
Drug: Budesonide/formoterol (Symbicort
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol (Symbicort Turbuhaler SMART™), starting dose 160 mg/4.5 mg two inhalations twice daily plus as-needed inhalations
Study: 22607479
Drug: Salmeterol/fluticasone propionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol/fluticasone propionate (Seretide Diskus), starting dose 50 mg/250 mg bid plus salbutamol as needed
Study: 20819525
Drug: Somatostatin administration
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin administration (group B)
Study: 15763644
Drug: tamoxifen monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: tamoxifen monotherapy
Study: 12086367
Drug: Combination montelukast
Normalized name: montelukast, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination montelukast 10 mg and loratadine 10 mg
Study: 12086367
Drug: Montelukast/loratadine vs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast/loratadine vs each therapy alone
Study: 9793700
Drug: s.c. naratriptan
Approvals — FDA: no, EMA: no, PMDA: no
Description: s.c. naratriptan 1 mg
Study: 9793700
Drug: s.c. naratriptan
Approvals — FDA: no, EMA: no, PMDA: no
Description: s.c. naratriptan 5 mg
Study: 9793700
Drug: s.c. naratriptan
Approvals — FDA: no, EMA: no, PMDA: no
Description: s.c. naratriptan 10 mg
Study: 7629756
Drug: 150 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 micrograms Atrial natriuretic hormone (ANH)
Study: 351073
Drug: Levamisole (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole (2.5 mg/kg on two consecutive days each week for six months)
Study: 31130273
Drug: Adductor canal
Normalized name: Canalevia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adductor canal block (ACB) with ropivacaine 0.5%, 20 ml
Study: 31130273
Drug: Local infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local infiltration analgesia (LIA) with ropivacaine 0.5%, 20 ml
Study: 24828126
Drug: Conventional hope
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional hope box integrated into VA behavioral health treatment
Study: 21106046
Drug: Brimonidine twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brimonidine twice daily (BID)
Study: 21106046
Drug: Brimonidine three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brimonidine three times daily (TID)
Study: 19765430
Drug: Basiliximab (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basiliximab (2 doses)
Study: 19765430
Drug: Daclizumab (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclizumab (5 doses)
Study: 16751166
Drug: Intra-articular hylan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular hylan G-F 20
Study: 11063767
Drug: Ketoprofen (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen (100 mg in 50 mL saline, warmed to 37 degrees C)
Study: 11063767
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 mL distilled water in 50 mL saline)
Study: 9093709
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (5-fluorouracil and levamisole)
Study: 8096373
Drug: Zidovudine (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine (two daily doses)
Study: 3532335
Drug: Low-dose (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose (1 MU/m2) subcutaneous (SC) treatment 5 days per week, every other week, for eight weeks
Study: 3532335
Drug: High-dose (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose (50 MU/m2) intravenous (IV) treatment 5 days per week, every other week, for eight weeks
Study: 3532335
Drug: High-dose (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose (30 MU/m2) intravenous (IV) treatment three times per week for eight weeks
Study: 3532335
Drug: Combined use
Normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined use of alpha interferon and chemotherapeutic agents (VP-16 and vinblastine)
Study: 19059736
Drug: Classroom‐Centered (CC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classroom‐Centered (CC) intervention
Study: 12723461
Drug: RWJ 67657
Normalized name: RWJ-800088
DrugBank: RWJ-800088 (DB18693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RWJ 67657 (10 mg/kg)
Study: 12723461
Drug: RWJ 67657
Normalized name: RWJ-800088
DrugBank: RWJ-800088 (DB18693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RWJ 67657 (20 mg/kg)
Study: 12723461
Drug: RWJ 67657
Normalized name: RWJ-800088
DrugBank: RWJ-800088 (DB18693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RWJ 67657 (0.25-30 mg/kg)
Study: 11730394
Drug: Unopposed micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unopposed micronized 17beta‐estradiol (1 mg/d)
Study: 11730394
Drug: Unopposed micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unopposed micronized 17beta‐estradiol (1 mg/d) among women who did not receive lipid‐lowering medication
Study: 11730394
Drug: Placebo among
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo among women who did not receive lipid‐lowering medication
Study: 11730394
Drug: Unopposed micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unopposed micronized 17beta‐estradiol (1 mg/d) among women who took lipid‐lowering medication
Study: 11730394
Drug: Placebo among
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo among women who took lipid‐lowering medication
Study: 9213324
Drug: Docetaxel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (75 mg/m2) + Doxorubicin (50 mg/m2) + Cyclophosphamide (500 mg/m2) for 8 courses
Study: 9213324
Drug: Docetaxel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (75 mg/m2) + Doxorubicin (50 mg/m2) + Cyclophosphamide (500 mg/m2) for 4 to 6 courses followed by high-dose chemotherapy with autologous peripheral blood stem-cell transplantation
Study: 9213324
Drug: Docetaxel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (75 mg/m2) + Doxorubicin (50 mg/m2) + Cyclophosphamide (500 mg/m2) for 4 to 6 courses with G-CSF (filgrastim) followed by high-dose chemotherapy with autologous peripheral blood stem-cell transplantation
Study: 2455105
Drug: Lisinopril, 20
Normalized name: Lisinopril, 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril, 20 mg
Study: 2455105
Drug: Nifedipine and
Normalized name: nifedipine and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine and Lisinopril combination
Study: 29549005
Drug: Nitrate supplement
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate supplement group (beetroot juice)
Study: 25684765
Drug: 3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg infliximab (IFX) therapy
Study: 25684765
Drug: 6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/kg or 10 mg/kg infliximab (IFX) therapy
Study: 3301505
Drug: Diltiazem (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (300 mg/die)
Study: 3301505
Drug: Nifedipine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (50 mg/die)
Study: 3301505
Drug: Verapamil (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (400 mg/die)
Study: 29911074
Drug: 28-day miltefosine
Normalized name: Miltefosine
DrugBank: Miltefosine (DB09031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 28-day miltefosine monotherapy
Study: 29911074
Drug: 11-day combination
Normalized name: Recombinant interleukin-11
DrugBank: Oprelvekin (DB00038)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 11-day combination therapy of miltefosine and liposomal amphotericin B (L-AMB)
Study: 29911074
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (L-AMB)
Study: 25142196
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy (CT) combined with antidepressant medication (ADM)
Study: 25142196
Drug: Antidepressant medication
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant medication (ADM) alone
Study: 23363666
Drug: Daily bathing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily bathing in chlorhexidine gluconate (CHG) 2%
Study: 20092709
Drug: Erythromycin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (200 mg intravenous drip, once every 12 hours)
Study: 20092709
Drug: Metoclopramide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (10 mg intravenous injection, once every 8 hours)
Study: 20092709
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Erythromycin and Metoclopramide)
Study: 17932089
Drug: Full-CAT (Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-CAT (Cognitive Adaptation Training focused on community adaptation including grooming, care of living quarters, leisure skills, social and role performance, and medication adherence)
Study: 17932089
Drug: Pharm-CAT (Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharm-CAT (Cognitive Adaptation Training focused only on medication and appointment adherence)
Study: 7648374
Drug: Loratadine 10
Normalized name: loratadine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loratadine 10 mg/d
Study: 2670634
Drug: 200 mg/day
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/day nimesulide
Study: 11319723
Drug: Dietary cholesterol
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary cholesterol intake of up to approximately 800 mg/day
Study: 11319723
Drug: Insulin-resistant women
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-resistant women
Study: 21775510
Drug: Insulin-sensitive women
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-sensitive women
Study: 31208472
Drug: Water for
Normalized name: WATER FOR INJECTION
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water for injection (WFI)